Arizona State Retirement System Holding in At&T (T) Lowered by $1.97 Million; Pitcairn Company Decreased Holding in Alexion Pharmaceuticals (ALXN) as Market Valuation Declined

December 7, 2017 - By Peter Erickson

Pitcairn Company decreased its stake in Alexion Pharmaceuticals Inc (ALXN) by 64.75% based on its latest 2017Q2 regulatory filing with the SEC. Pitcairn Company sold 13,229 shares as the company’s stock declined 11.63% while stock markets rallied. The institutional investor held 7,202 shares of the health care company at the end of 2017Q2, valued at $876,000, down from 20,431 at the end of the previous reported quarter. Pitcairn Company who had been investing in Alexion Pharmaceuticals Inc for a number of months, seems to be less bullish one the $24.45 billion market cap company. The stock increased 0.48% or $0.52 during the last trading session, reaching $109.42. About 1.94M shares traded. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has declined 18.12% since December 7, 2016 and is downtrending. It has underperformed by 34.82% the S&P500.

Arizona State Retirement System decreased its stake in At&T Inc (T) by 2.36% based on its latest 2017Q2 regulatory filing with the SEC. Arizona State Retirement System sold 53,117 shares as the company’s stock declined 7.81% while stock markets rallied. The institutional investor held 2.19 million shares of the telecommunications equipment company at the end of 2017Q2, valued at $82.74 million, down from 2.25 million at the end of the previous reported quarter. Arizona State Retirement System who had been investing in At&T Inc for a number of months, seems to be less bullish one the $221.68 billion market cap company. The stock decreased 1.20% or $0.44 during the last trading session, reaching $36.11. About 31.17M shares traded. AT&T Inc. (NYSE:T) has declined 0.52% since December 7, 2016 and is downtrending. It has underperformed by 17.22% the S&P500.




Since June 14, 2017, it had 4 buys, and 1 sale for $235.75 million activity. On Wednesday, June 14 HANTSON LUDWIG bought $1.17M worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) or 10,000 shares. BAKER BROS. ADVISORS LP bought $77.53 million worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) on Wednesday, June 14. PARVEN ALVIN S also sold $97,511 worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) on Thursday, June 15.

Pitcairn Company, which manages about $832.81 million US Long portfolio, upped its stake in Celanese Corp Del (NYSE:CE) by 4,947 shares to 7,682 shares, valued at $729,000 in 2017Q2, according to the filing. It also increased its holding in Mcdonalds Corp (NYSE:MCD) by 3,085 shares in the quarter, for a total of 22,285 shares, and has risen its stake in Coherent Inc (NASDAQ:COHR).

Analysts await Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) to report earnings on February, 15. They expect $1.09 earnings per share, down 0.91% or $0.01 from last year’s $1.1 per share. ALXN’s profit will be $243.52M for 25.10 P/E if the $1.09 EPS becomes a reality. After $1.28 actual earnings per share reported by Alexion Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -14.84% negative EPS growth.

Among 28 analysts covering Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), 22 have Buy rating, 0 Sell and 6 Hold. Therefore 79% are positive. Alexion Pharmaceuticals Inc. had 86 analyst reports since July 27, 2015 according to SRatingsIntel. Barclays Capital maintained the stock with “Equal-Weight” rating in Friday, July 29 report. Oppenheimer upgraded the shares of ALXN in report on Thursday, July 27 to “Buy” rating. The company was maintained on Thursday, July 27 by Cowen & Co. Barclays Capital upgraded Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) on Tuesday, November 29 to “Overweight” rating. The firm earned “Equal-Weight” rating on Tuesday, December 13 by Morgan Stanley. The company was maintained on Friday, July 28 by Morgan Stanley. The rating was maintained by BMO Capital Markets with “Buy” on Friday, July 21. Credit Suisse upgraded it to “Outperform” rating and $165 target in Monday, July 11 report. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) earned “Outperform” rating by RBC Capital Markets on Wednesday, July 13. The firm has “Outperform” rating by RBC Capital Markets given on Friday, February 17.

Investors sentiment increased to 1.37 in 2017 Q2. Its up 0.23, from 1.14 in 2017Q1. It improved, as 55 investors sold ALXN shares while 146 reduced holdings. 72 funds opened positions while 203 raised stakes. 208.01 million shares or 0.31% less from 208.67 million shares in 2017Q1 were reported. Panagora Asset Mgmt holds 0% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 9,472 shares. Fund Mgmt Sa stated it has 478,692 shares. Thrivent Fincl For Lutherans holds 0.43% or 852,166 shares. Putnam Invests Llc has 0% invested in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). New York-based Metropolitan Life Insurance New York has invested 0.1% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Zurcher Kantonalbank (Zurich Cantonalbank) invested in 0.05% or 42,451 shares. Stevens Capital Management Ltd Partnership stated it has 0.31% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Tarbox Family Office Inc, a California-based fund reported 20 shares. Samlyn Ltd Llc accumulated 84,100 shares or 0.25% of the stock. National Bank Of The West reported 49,144 shares. Glg Ltd Liability Co accumulated 0.32% or 42,772 shares. Bp Public Lc invested in 0.12% or 26,000 shares. Numeric Investors Limited Liability Company invested in 0.01% or 5,200 shares. 1.00M were reported by Deutsche Bank Ag. Sumitomo Mitsui Asset Management Company holds 18,007 shares or 0.04% of its portfolio.

More notable recent Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) news were published by: Investorplace.com which released: “3 Big Stock Charts for Wednesday: Alexion Pharmaceuticals, Inc., Alliance Data …” on November 15, 2017, also Streetinsider.com with their article: “Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) Names Francois Nader to Board of …” published on November 08, 2017, Seekingalpha.com published: “Alexion Pharma – Underperformance Does Not Equal Opportunity” on November 20, 2017. More interesting news about Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) were released by: Forbes.com and their article: “Biotech Pullback Makes Bargains Out Of Alexion, Flexion, Clovis, Tesaro And Incyte” published on November 28, 2017 as well as Streetinsider.com‘s news article titled: “Alexion Pharma (ALXN), Halozyme (HALO) Enter License Agreement for ENHANZE …” with publication date: December 07, 2017.

Among 29 analysts covering AT&T Inc. (NYSE:T), 10 have Buy rating, 1 Sell and 18 Hold. Therefore 34% are positive. AT&T Inc. had 67 analyst reports since July 27, 2015 according to SRatingsIntel. As per Monday, April 18, the company rating was maintained by Barclays Capital. Citigroup upgraded it to “Buy” rating and $37 target in Wednesday, September 2 report. The stock of AT&T Inc. (NYSE:T) has “Mkt Perform” rating given on Friday, July 22 by FBR Capital. Drexel Hamilton downgraded the stock to “Hold” rating in Monday, October 24 report. The firm has “Sector Perform” rating by RBC Capital Markets given on Thursday, January 26. The stock of AT&T Inc. (NYSE:T) has “Outperform” rating given on Wednesday, October 25 by Robert W. Baird. As per Tuesday, July 25, the company rating was maintained by Oppenheimer. The company was maintained on Friday, July 7 by RBC Capital Markets. Oppenheimer maintained the shares of T in report on Tuesday, August 8 with “Hold” rating. Moffet Nathanson downgraded the stock to “Sell” rating in Friday, April 1 report.

Arizona State Retirement System, which manages about $7.22B US Long portfolio, upped its stake in Cvs Health Corp (NYSE:CVS) by 77,813 shares to 340,247 shares, valued at $27.38 million in 2017Q2, according to the filing. It also increased its holding in Exxon Mobil Corp (NYSE:XOM) by 42,183 shares in the quarter, for a total of 1.41 million shares, and has risen its stake in People S United Financial (NASDAQ:PBCT).

Investors sentiment increased to 1.15 in Q2 2017. Its up 0.18, from 0.97 in 2017Q1. It improved, as 82 investors sold T shares while 619 reduced holdings. 123 funds opened positions while 686 raised stakes. 3.31 billion shares or 0.46% less from 3.32 billion shares in 2017Q1 were reported. Farmers holds 43,007 shares or 0.57% of its portfolio. Capital reported 13.86 million shares or 0.7% of all its holdings. Caprock Gp Inc has invested 0.53% in AT&T Inc. (NYSE:T). Puplava Fincl reported 73,303 shares. Synovus invested in 973,234 shares. Guardian Life Insur Of America holds 0.08% or 13,908 shares. Moreover, Raymond James Trust Na has 1.24% invested in AT&T Inc. (NYSE:T). Salzhauer Michael owns 0.13% invested in AT&T Inc. (NYSE:T) for 7,295 shares. Arrow Fin Corp accumulated 0.23% or 25,660 shares. Fairfield Bush accumulated 0.75% or 62,316 shares. Marietta Investment Prtn Ltd Com stated it has 17,332 shares or 0.21% of all its holdings. Public Sector Pension Invest Board reported 701,216 shares. Lehman Fincl Res Inc has invested 0.32% in AT&T Inc. (NYSE:T). Legg Mason Asset Mgmt (Japan) Ltd holds 30,800 shares or 0.95% of its portfolio. Autus Asset Limited Liability Co holds 5,637 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.